HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Atossa Therapeutics (NASDAQ:ATOS) and maintained a $4 price target.
April 16, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics receives a reiterated Buy rating and a maintained $4 price target from HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards ATOS. This endorsement may lead to increased investor confidence in the stock, potentially driving its price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100